Published in AIDS Weekly, June 2nd, 1997
The MAb, dubbed B4, was developed by United Biomedical Inc. (UBI), Hauppage, New York.
"B4, in humanized form, is a promising candidate for use in post-exposure prophylaxis," said Carl V. Hanson of the California Department of Health Services, Berkeley, California. "A new approach to HIV vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.